
MiNK Therapeutics (INKT) Stock Forecast & Price Target
MiNK Therapeutics (INKT) Analyst Ratings
Bulls say
MiNK Therapeutics is seen as a strong buy with a projected price target of $35 based on its promising allogeneic, off-the-shelf, native iNKT cell therapy agenT-797 and its potential in treating cancer and other immune-mediated diseases. While there are inherent risks in the development and commercialization of novel therapies, the company's strong technology platform, current pipeline assets, and indications show potential for success and growth in the biopharmaceutical industry. MiNK may face challenges such as safety concerns and competition, but its current financial position and potential for continued financing suggest a bright future for the company.
Bears say
MiNK Therapeutics is a clinical-stage biopharmaceutical company with a negative stock outlook due to its heavy reliance on external capital and lack of FDA-approved therapies. While their agenT-797 shows promise in treating pneumonia and GvHD, the company's Phase 2 trials are not expected to yield results until 2H26. In addition, the company has no formal collaborations or agreements in place. Their highly-anticipated external GvHD trial is not expected to begin dosing until 2H26, which could negatively impact investor confidence.
This aggregate rating is based on analysts' research of MiNK Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
MiNK Therapeutics (INKT) Analyst Forecast & Price Prediction
Start investing in MiNK Therapeutics (INKT)
Order type
Buy in
Order amount
Est. shares
0 shares